0.2810EUR-1.06%Mkt Cap: —P/E: —1d ago
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value11.96M $
Revenue (TTM)22.83K $
Gross Profit14.13K $
Net Income (TTM)902.17K $
Revenue/Share0.0000 USD
Last Price0.2810 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS1512052002
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-7.24
EV/Revenue524.02
P/S—
P/B5.26
EPS (TTM)-1.44
EPS (Forward)—
52W Range
0.273073% of range0.2840
52W High0.2840 EUR
52W Low0.2730 EUR
Profitability
Gross Margin61.90%
Oper. Margin30414.28%
EBITDA Margin0.00%
Profit Margin3952.38%
ROE56.33%
ROA-13.40%
Growth
Revenue Growth-95.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.50M $
CapEx (TTM)—
FCF Margin-5038.69%
FCF Yield—
Net Debt-1.86M $
Net Debt/EBITDA1.12
Balance Sheet
Debt/Equity—
Current Ratio1.92
Quick Ratio1.38
Book Value/Sh0.0540 EUR
Cash/Share0.0380 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.11.94M
Float14.15M
Insiders10.28%
Institutions55.49%
Technical
SMA 500.5072 (-44.6%)
SMA 2000.6023 (-53.3%)
Beta1.21
S&P 52W Chg20.80%
Avg Vol (30d)25
Avg Vol (10d)1.54K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—